United Therapeutics vs Regeneron Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

United Therapeutics Corporation (UTHR)

Q3 202612 Jul – 2 Oct 2026

▲4▼3

Legal Win and Organ Flights Boost UTHR, but Competition and Analyst Caution Linger

Court Blocks Liquidia's Yutrepia in PH-ILD A Delaware court blocked Liquidia's Yutrepia in PH-ILD, a key lung disease. This protects UTHR's Tyvaso franchise and sent shares up 12.5%.
This legal win directly removes a competitive threat and caused a sharp stock jump.
Manufactured Organs Flown on eVTOL United Therapeutics advanced its organ-delivery story by flying manufactured organs on the first U.S. eVTOL pilot flights, moving closer to its long-term goal of providing transplantable organs.
This milestone supports the company's long-term growth narrative and differentiates it from peers.
Phase 3 Data Supports Two FDA Filings New Phase 3 data supported two FDA filings, potentially expanding UTHR's product labels and driving future revenue growth.
Positive clinical data and regulatory filings are key catalysts for future sales.
Accelerated Buyback Returns $477.6 Million UTHR returned $477.6 million to shareholders via an accelerated buyback, signaling confidence and supporting the stock price.
Buybacks reduce share count and often boost investor sentiment.
Liquidia's Yutrepia Gains PAH Share Liquidia's Yutrepia continues to gain share in PAH, threatening UTHR's Tyvaso franchise. This competitive pressure weighs on the stock.
Ongoing competitive threat to core revenue stream.
Judge Criticizes Deceptive Patent Document A judge criticized UTHR for a deceptive, backdated patent-fight document, raising legal and reputational concerns.
This legal issue could lead to penalties and damage trust.
Goldman Sachs Initiates with Sell Rating Goldman Sachs initiated coverage with a Sell rating, doubting UTHR's 2029 targets. This analyst caution adds pressure on the stock.
Analyst downgrade can influence investor sentiment and stock performance.
New Tresmi Inhaler Could Defend Tyvaso The new Tresmi inhaler could help defend the Tyvaso franchise against competition, but its impact is uncertain and competition remains intense.
Potential positive product but not yet proven, so mixed effect.

September 20265 Aug – 2 Oct 2026

▲3▼1

UTHR wins key patent ruling, but competition and analyst caution weigh

Court ruling blocks rival Yutrepia in PH-ILD A Delaware court ruled that Liquidia's Yutrepia infringes United Therapeutics' patent on inhaled treprostinil for PH-ILD. This could restrict Yutrepia's use in that lung condition, reducing competition for UTHR's Tyvaso and Tyvaso DPI, and UTHR may also win money damages. The stock jumped 12.5% on the news.
This is the biggest new event, directly lifting UTHR by weakening a rival and protecting its top-selling franchise.
New data supports two FDA filings United Therapeutics presented new analyses from its Phase 3 trials of ralinepag and inhaled treprostinil for IPF at European medical meetings. The data showed clinical benefits, supporting two FDA applications filed in June. If approved, these could expand UTHR's treatable patient groups and add billions in revenue.
This is a fresh positive catalyst that strengthens the case for two potential new products.
Company returns $477.6 million to shareholders United Therapeutics committed the last $477.6 million of its $2 billion buyback to an accelerated share repurchase. This brings total capital returned to about $4 billion in two and a half years. Buybacks reduce the number of shares, which can lift earnings per share and support the stock price.
This is a new capital-return action that directly affects share count and investor sentiment.
Goldman Sachs starts coverage with Sell rating Goldman Sachs initiated coverage of United Therapeutics with a Sell rating, questioning whether the company can hit its 2029 revenue and earnings targets. The analyst doubts the ambitious pipeline can deliver as expected. This adds a fresh negative voice and could pressure the stock until upcoming FDA decisions provide clarity.
This is a new analyst action that introduces a notable counterweight to the positive patent news.

Latest5 Aug – 2 Oct 2026

▲3▼1

UTHR wins key patent ruling, but competition and analyst caution weigh

Court ruling blocks rival Yutrepia in PH-ILD A Delaware court ruled that Liquidia's Yutrepia infringes United Therapeutics' patent on inhaled treprostinil for PH-ILD. This could restrict Yutrepia's use in that lung condition, reducing competition for UTHR's Tyvaso and Tyvaso DPI, and UTHR may also win money damages. The stock jumped 12.5% on the news.
This is the biggest new event, directly lifting UTHR by weakening a rival and protecting its top-selling franchise.
New data supports two FDA filings United Therapeutics presented new analyses from its Phase 3 trials of ralinepag and inhaled treprostinil for IPF at European medical meetings. The data showed clinical benefits, supporting two FDA applications filed in June. If approved, these could expand UTHR's treatable patient groups and add billions in revenue.
This is a fresh positive catalyst that strengthens the case for two potential new products.
Company returns $477.6 million to shareholders United Therapeutics committed the last $477.6 million of its $2 billion buyback to an accelerated share repurchase. This brings total capital returned to about $4 billion in two and a half years. Buybacks reduce the number of shares, which can lift earnings per share and support the stock price.
This is a new capital-return action that directly affects share count and investor sentiment.
Goldman Sachs starts coverage with Sell rating Goldman Sachs initiated coverage of United Therapeutics with a Sell rating, questioning whether the company can hit its 2029 revenue and earnings targets. The analyst doubts the ambitious pipeline can deliver as expected. This adds a fresh negative voice and could pressure the stock until upcoming FDA decisions provide clarity.
This is a new analyst action that introduces a notable counterweight to the positive patent news.

July 202612 Jul – 22 Jul 2026

▲2▼2

UTHR's organ-delivery flights advance, but PAH competition and patent setback weigh

Manufactured organs flown on first eVTOL pilot flights United Therapeutics' manufactured organs were carried on the first US eVTOL integration pilot flights between Virginia and Maryland. This shows a real use for its organ products and could open a new delivery route, supporting the long-term growth story that helps lift the stock.
New concrete validation of UTHR's organ business and logistics use case.
Liquidia's Yutrepia keeps taking PAH market share Liquidia's competing PAH drug Yutrepia posted about $130 million in first-quarter sales, with thousands of patients starting it. It is winning new patients and expanding into more lung conditions, which threatens United Therapeutics' core Tyvaso franchise and caps the stock's upside.
Shows the competitive threat to UTHR's main revenue source is growing.
Judge criticizes United Therapeutics in patent fight A judge said United Therapeutics gave a deceptive and backdated answer in its patent dispute with Liquidia, and asked who changed the document. The stock slipped on the news. A bad ruling could weaken UTHR's legal position against a rival, so investors see added risk.
New legal setback that could affect UTHR's ability to defend its PAH patents.
New Tresmi inhaler could defend the Tyvaso franchise United Therapeutics unveiled Tresmi, a soft-mist inhaler its CEO called a category killer. It could replace lost Tyvaso DPI royalties and help hold off rivals like Yutrepia. A strong new product supports future sales, which is good for the stock.
New product that may offset competitive and royalty pressures on UTHR's PAH business.

12 Jul – 22 Jul 2026

▲2▼2

UTHR's organ-delivery flights advance, but PAH competition and patent setback weigh

Manufactured organs flown on first eVTOL pilot flights United Therapeutics' manufactured organs were carried on the first US eVTOL integration pilot flights between Virginia and Maryland. This shows a real use for its organ products and could open a new delivery route, supporting the long-term growth story that helps lift the stock.
New concrete validation of UTHR's organ business and logistics use case.
Liquidia's Yutrepia keeps taking PAH market share Liquidia's competing PAH drug Yutrepia posted about $130 million in first-quarter sales, with thousands of patients starting it. It is winning new patients and expanding into more lung conditions, which threatens United Therapeutics' core Tyvaso franchise and caps the stock's upside.
Shows the competitive threat to UTHR's main revenue source is growing.
Judge criticizes United Therapeutics in patent fight A judge said United Therapeutics gave a deceptive and backdated answer in its patent dispute with Liquidia, and asked who changed the document. The stock slipped on the news. A bad ruling could weaken UTHR's legal position against a rival, so investors see added risk.
New legal setback that could affect UTHR's ability to defend its PAH patents.
New Tresmi inhaler could defend the Tyvaso franchise United Therapeutics unveiled Tresmi, a soft-mist inhaler its CEO called a category killer. It could replace lost Tyvaso DPI royalties and help hold off rivals like Yutrepia. A strong new product supports future sales, which is good for the stock.
New product that may offset competitive and royalty pressures on UTHR's PAH business.

Q2 202617 Jun – 9 Jul 2026

▲2▼2

Pipeline Wins and New Deals Offset Weak Sales and Rising Competition

FDA Approves LungFX Device United Therapeutics won FDA approval for its LungFX device, which helps assess donor lungs that would otherwise be discarded. This opens a new revenue stream in organ transplantation and supports the company's long-term growth story, pushing the stock up.
This is a new regulatory win that expands the company's business and is a fresh positive catalyst.
Acquires Thymmune for $140 Million United Therapeutics bought Thymmune Therapeutics for $140 million cash, adding a regenerative thymic cell therapy platform. This expands its pipeline in organ transplantation and immune therapies, signaling long-term growth and boosting investor confidence.
A new acquisition that adds technology and pipeline depth, directly affecting future growth prospects.
Q1 Revenue Miss and Decline United Therapeutics reported Q1 revenue of $781.5 million, down 1.6% from a year ago and missing estimates. This weak financial performance, especially compared to peers, weighs on the stock as investors worry about near-term sales trends.
A new earnings report showing a revenue miss and decline, which directly pressures the stock price.
Liquidia's YUTREPIA Gains Ground Liquidia's competing PAH drug YUTREPIA is growing fast, with annualized revenue near $520 million and most new patients treatment-naive. This competition threatens United Therapeutics' core PAH franchise, especially as its nebulized Tyvaso sales decline, capping upside.
A new update on a direct competitor's rapid growth, which increases competitive pressure on UTHR's key products.

June 202617 Jun – 9 Jul 2026

▲2▼2

Pipeline Wins and New Deals Offset Weak Sales and Rising Competition

FDA Approves LungFX Device United Therapeutics won FDA approval for its LungFX device, which helps assess donor lungs that would otherwise be discarded. This opens a new revenue stream in organ transplantation and supports the company's long-term growth story, pushing the stock up.
This is a new regulatory win that expands the company's business and is a fresh positive catalyst.
Acquires Thymmune for $140 Million United Therapeutics bought Thymmune Therapeutics for $140 million cash, adding a regenerative thymic cell therapy platform. This expands its pipeline in organ transplantation and immune therapies, signaling long-term growth and boosting investor confidence.
A new acquisition that adds technology and pipeline depth, directly affecting future growth prospects.
Q1 Revenue Miss and Decline United Therapeutics reported Q1 revenue of $781.5 million, down 1.6% from a year ago and missing estimates. This weak financial performance, especially compared to peers, weighs on the stock as investors worry about near-term sales trends.
A new earnings report showing a revenue miss and decline, which directly pressures the stock price.
Liquidia's YUTREPIA Gains Ground Liquidia's competing PAH drug YUTREPIA is growing fast, with annualized revenue near $520 million and most new patients treatment-naive. This competition threatens United Therapeutics' core PAH franchise, especially as its nebulized Tyvaso sales decline, capping upside.
A new update on a direct competitor's rapid growth, which increases competitive pressure on UTHR's key products.

17 Jun – 9 Jul 2026

▲2▼2

Pipeline Wins and New Deals Offset Weak Sales and Rising Competition

FDA Approves LungFX Device United Therapeutics won FDA approval for its LungFX device, which helps assess donor lungs that would otherwise be discarded. This opens a new revenue stream in organ transplantation and supports the company's long-term growth story, pushing the stock up.
This is a new regulatory win that expands the company's business and is a fresh positive catalyst.
Acquires Thymmune for $140 Million United Therapeutics bought Thymmune Therapeutics for $140 million cash, adding a regenerative thymic cell therapy platform. This expands its pipeline in organ transplantation and immune therapies, signaling long-term growth and boosting investor confidence.
A new acquisition that adds technology and pipeline depth, directly affecting future growth prospects.
Q1 Revenue Miss and Decline United Therapeutics reported Q1 revenue of $781.5 million, down 1.6% from a year ago and missing estimates. This weak financial performance, especially compared to peers, weighs on the stock as investors worry about near-term sales trends.
A new earnings report showing a revenue miss and decline, which directly pressures the stock price.
Liquidia's YUTREPIA Gains Ground Liquidia's competing PAH drug YUTREPIA is growing fast, with annualized revenue near $520 million and most new patients treatment-naive. This competition threatens United Therapeutics' core PAH franchise, especially as its nebulized Tyvaso sales decline, capping upside.
A new update on a direct competitor's rapid growth, which increases competitive pressure on UTHR's key products.

Regeneron Pharmaceuticals Inc (REGN)

Q3 20264 Jul – 1 Oct 2026

▲1▼1

Regeneron's Q3: Pipeline Wins, Melanoma Setback, Sanofi Deal

Q2 earnings beat with 17% revenue growth Regeneron's Q2 revenue rose 17% to $4.29 billion, beating estimates, driven by strong Dupixent and high-dose Eylea sales, while Sanofi repayment improved margins.
Strong financial results directly boost investor confidence and the stock price.
Failed melanoma trial triggers lawsuits and $11B value loss A failed melanoma trial led to securities lawsuits and wiped out $11 billion in market value, highlighting pipeline execution risks and disappointing investors.
This major setback significantly impacted Regeneron's market value and reputation.
Sanofi alliance expands with $1B upfront but Dupixent profit-sharing unchanged Sanofi's expanded alliance brought $1 billion upfront and up to $7 billion in milestones, but left Dupixent profit-sharing unchanged, causing shares to drop 4%.
The deal has both positive financial aspects and negative implications for Dupixent economics.

September 202617 Sep – 1 Oct 2026

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.
This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.
Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.
A positive clinical readout in a major new market area is a key driver of future growth expectations.
Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.
Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.
Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.
It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

Latest17 Sep – 1 Oct 2026

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.
This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.
Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.
A positive clinical readout in a major new market area is a key driver of future growth expectations.
Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.
Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.
Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.
It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

August 202627 Jul – 4 Sep 2026

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.
This is the period's biggest positive fundamental driver of REGN's value.
Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.
It is a concrete capital event that improves future profitability.
FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.
A new FDA approval is a fresh product and pipeline milestone for REGN.
Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.
This is the main negative overhang on REGN this period.

27 Jul – 4 Sep 2026

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.
This is the period's biggest positive fundamental driver of REGN's value.
Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.
It is a concrete capital event that improves future profitability.
FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.
A new FDA approval is a fresh product and pipeline milestone for REGN.
Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.
This is the main negative overhang on REGN this period.

July 20264 Jul – 24 Jul 2026

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.
This is a new positive regulatory catalyst that could drive future revenue and investor optimism.
Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.
This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.
Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.
This new analyst commentary underscores pipeline challenges that could pressure the stock.

4 Jul – 24 Jul 2026

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.
This is a new positive regulatory catalyst that could drive future revenue and investor optimism.
Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.
This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.
Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.
This new analyst commentary underscores pipeline challenges that could pressure the stock.

Q2 202619 Jun – 25 Jun 2026

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.
This is a new deal that adds to Regeneron's pipeline and potential future earnings.
Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.
Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.
FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.
This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.
AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.
This is a new competitive threat that could impact Regeneron's key product, Dupixent.

June 202619 Jun – 25 Jun 2026

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.
This is a new deal that adds to Regeneron's pipeline and potential future earnings.
Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.
Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.
FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.
This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.
AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.
This is a new competitive threat that could impact Regeneron's key product, Dupixent.

19 Jun – 25 Jun 2026

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.
This is a new deal that adds to Regeneron's pipeline and potential future earnings.
Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.
Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.
FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.
This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.
AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.
This is a new competitive threat that could impact Regeneron's key product, Dupixent.